Effectiveness of High-Volume Therapeutic Plasma Exchange for Acute and Acute-on-Chronic Liver Failure in Korean Pediatric Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Liver transplantation (LT) is the only curative treatment for acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). In high-volume therapeutic plasma exchange (HV-TPE), extracorporeal liver support filters accumulate toxins and improve the coagulation factor by replacing them. In this study, we aimed to evaluate the effectiveness of HV-TPE in pediatric patients with ALF and ACLF. Methods: We reviewed the records of children waiting for LT at Severance Hospital who underwent HV-TPE between 2017 and 2021. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total and direct bilirubin (TB and DB), gamma-glutamyl transferase (GGT), ammonia, and coagulation parameter-international normalized ratio (INR) were all measured before and after HV-TPE to analyze the liver function. The statistical analysis was performed using IBM SPSS Statistics for Windows, version 26.0 (IBM Co., Armonk, NY, USA). Results: Nine patients underwent HV-TPE with standard medical therapy while waiting for LT. One had neonatal hemochromatosis, four had biliary atresia, and the other four had ALF of unknown etiology. Significant decreases in AST, ALT, TB, DB, GGT, and INR were noted after performing HV-TPE (930.38–331.75 IU/L, 282.62–63.00 IU/L, 11.75–5.59 mg/dL, 8.10– 3.66 mg/dL, 205.62–51.75 IU/L, and 3.57–1.50, respectively, p<0.05). All patients underwent LT, and two expired due to acute complications. Conclusion: HV-TPE could remove accumulated toxins and improve coagulation. Therefore, we conclude that HV-TPE can be regarded as a representative bridging therapy before LT.
Abstract
Purpose: Liver transplantation (LT) is the only curative treatment for acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). In high-volume therapeutic plasma exchange (HV-TPE), extracorporeal liver support filters accumulate toxins and improve the coagulation factor by replacing them. In this study, we aimed to evaluate the effectiveness of HV-TPE in pediatric patients with ALF and ACLF. Methods: We reviewed the records of children waiting for LT at Severance Hospital who underwent HV-TPE between 2017 and 2021. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total and direct bilirubin (TB and DB), gamma-glutamyl transferase (GGT), ammonia, and coagulation parameter-international normalized ratio (INR) were all measured before and after HV-TPE to analyze the liver function. The statistical analysis was performed using IBM SPSS Statistics for Windows, version 26.0 (IBM Co., Armonk, NY, USA). Results: Nine patients underwent HV-TPE with standard medical therapy while waiting for LT. One had neonatal hemochromatosis, four had biliary atresia, and the other four had ALF of unknown etiology. Significant decreases in AST, ALT, TB, DB, GGT, and INR were noted after performing HV-TPE (930.38–331.75 IU/L, 282.62–63.00 IU/L, 11.75–5.59 mg/dL, 8.10– 3.66 mg/dL, 205.62–51.75 IU/L, and 3.57–1.50, respectively, p<0.05). All patients underwent LT, and two expired due to acute complications. Conclusion: HV-TPE could remove accumulated toxins and improve coagulation. Therefore, we conclude that HV-TPE can be regarded as a representative bridging therapy before LT.
참고문헌 (14)
- Grama A, "Etiology and outcome of acute liver failure in children-the experience of a single tertiary care hospital from Romania", Children(Basel), 7, pp.282~ (2020)
- Maheshwari A, "Effects of therapeutic plasma exchange on liver function test and coagulation parameters in acute liver failure patients", Hematol Transfus Cell Ther, 42, pp.125~128 (2020)
- Julia Wendon, "EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure", Journal of Hepatology, 66(5), pp.1047~1081 (2017), Elsevier BV[DOI]
- Bernal W, "Acute liver failure", N Engl J Med, 369, pp.2525~2534 (2013)
- Larsen FS, "High-volume plasma exchange in patients with acute liver failure : an open randomised controlled trial", J Hepatol, 64, pp.69~78 (2016)
- Padmanabhan A, "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis : the eighth special issue", J Clin Apher, 34, pp.171~354 (2019)
- Verma N, "Plasma exchange for hemolytic crisis and acute liver failure in Wilson disease", Indian J Pediatr, 81, pp.498~500 (2014)
- Morgan SM, "Therapeutic plasma exchange for fulminant hepatic failure secondary to Wilson’s disease", J Clin Apher, 27, pp.282~286 (2012)
- McPhail MJ, "Ability of King’s College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure : a meta-analysis", Clin Gastroenterol Hepatol, 14, pp.516~525 (2016)[DOI]
- Barshes NR, "The pediatric end-stage liver disease(PELD)model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients", Liver Transpl, 12, pp.475~480 (2006)
- Tan EX, "Plasma exchange in patients with acute and acute-on-chronic liver failure : a systematic review", World J Gastroenterol, 26, pp.219~245 (2020)
- Chien MM, "Prognostic parameters of pediatric acute liver failure and the role of plasma exchange", Pediatr Neonatol, 60, pp.389~395 (2019)
- Possamai LA, "Modulation of monocyte", macrophage function : a therapeutic strategy in the treatment of acute liver failure, 2014, pp.61, 439~445
- Alexander EC, "Therapeutic plasma exchange in children with acute liver failure(ALF) : is it time for incorporation into the ALF armamentarium?", Pediatr Nephrol, 37, pp.1775~1788 (2022)